4 238

Cited 17 times in

Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension

Authors
 Chan Yun Kim  ;  Samin Hong  ;  Gong Je Seong 
Citation
 JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, Vol.23(5) : 481-486, 2007 
Journal Title
 JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS 
ISSN
 1080-7683 
Issue Date
2007
MeSH
Administration, Topical ; Adrenergic alpha-Agonists/administration & dosage ; Adrenergic alpha-Agonists/adverse effects ; Adrenergic alpha-Agonists/therapeutic use* ; Adult ; Antihypertensive Agents/administration & dosage ; Antihypertensive Agents/adverse effects ; Antihypertensive Agents/therapeutic use* ; Asia ; Asian Continental Ancestry Group ; Brimonidine Tartrate ; Conjunctivitis, Allergic/chemically induced ; Cross-Over Studies ; Female ; Humans ; Intraocular Pressure/drug effects ; Male ; Ocular Hypertension/drug therapy* ; Ophthalmic Solutions ; Pigment Epithelium of Eye/metabolism ; Preservatives, Pharmaceutical* ; Prospective Studies ; Quinoxalines/administration & dosage ; Quinoxalines/adverse effects ; Quinoxalines/therapeutic use* ; Single-Blind Method ; Therapeutic Equivalency
Abstract
PURPOSE: The aim of this study was to evaluate the efficacy and safety of brimonidine 0.2% versus brimonidine Purite 0.15% in Asians with ocular hypertension. METHODS: This study was a prospective, randomized, observer-masked, short-term crossover trial. Eighty-six (86) Asian subjects with newly diagnosed ocular hypertension were randomly assigned to receive either brimonidine 0.2% or brimonidine Purite 0.15%, both dosed twice a day for 4 weeks. Subjects were then washed out for 6 weeks and switched to the opposite treatment for 4 weeks. RESULTS: The baseline intraocular pressure (IOP) was 24.4 +/- 2.45 mmHg for brimonidine 0.2% and 24.39 +/- 2.56 mmHg for brimonidine Purite 0.15% (P = 0.985). The IOP was at trough drug effect after 4 weeks of brimonidine 0.2% and brimonidine Purite 0.15% therapy were 20.10 +/- 2.01 mmHg and 21.00 +/- 1.67 mmHg (P = 0.001), respectively. The IOP at peak drug effect after 4 weeks of brimonidine 0.2% and brimonidine Purite 0.15% treatment were 18.10 +/- 1.73 mmHg and 18.20 +/- 1.71 mmHg (P = 0.518), respectively. Brimonidine 0.2% was found to cause more allergic conjunctivitis than brimonidine Purite 0.15% (P < 0.001). CONCLUSIONS: Brimonidine 0.2% has a higher potency of lowering IOP than brimonidine Purite 0.15% at trough when used twice-daily. However, ocular allergic reaction was more frequent and severe with brimonidine 0.2% than with brimonidine Purite 0.15%.
Full Text
http://online.liebertpub.com/doi/abs/10.1089/jop.2007.0042
DOI
10.1089/jop.2007.0042
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Chan Yun(김찬윤) ORCID logo https://orcid.org/0000-0002-8373-9999
Seong, Gong Je(성공제) ORCID logo https://orcid.org/0000-0002-5456-4296
Hong, Sa Min(홍사민)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/96501
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse